2. EUROPEAN UROLOGY SUPPLEMENTS
“Terpenes in Urolithiasis” – Proceedings of the ROWA Symposium Düsseldorf, Germany, September 2010
Guest Editor: Thomas Knoll, Sindelfingen, Germany
Vol. 9, Issue 12, December 2010, Page No. 819-825
Overall, this Symposium specifically dealt with the management and treatment of Urolithiasis which clearly illustrates from the various references outlined that the product ROWATINEX demonstrates the superiority of the terpene combination compared to Placebo in the treatment of urinary stone-related symptoms.
ROWATINEX has its defined place in the pharmacological armamentarium of Urolithiasis.
Please refer to pages 819-825 in which the above clinical trial is featured.
http://www.europeanurology-supplement.com/article/PIIS1569905610001557/fulltext
3. UROLOGIA INTERNATIONALIS
“A Special Terpene Combination (Rowatinex®) Improves Stone Clearance after Extracorporeal Shockwave Lithotripsy in Urolithiasis Patients: Results of a Placebo-Controlled Randomised Controlled Trial”
Imre Romics, György Siller, Ralf Kohnen, Stelios Mavrogenis, József Varga, Endre Holman
Vol. 86, No. 1, 2011, Page No. 102-109
The objective of this study was to investigate the safety and efficacy of a special terpene combination in the treatment of patients with Urolithiasis after extracorporeal shockwave lithotripsy (ESWL).
Overall, this is the first randomised, double-blind, Placebo-controlled multi-centre study demonstrating the superiority of the terpene combination as compared to Placebo (see also Point 1 – Integrated Clinical and Statistical Study Report) with respect to the rate of stone-free patients and the time to stone-free status
during 12 weeks of treatment after ESWL. Treatment with the terpene combination was well tolerated and safe. The terpene combination was found to be an efficacious treatment in eliminating calculi fragments generated by ESWL as compared to Placebo.
4. SUMMARY
The Study Report, together with the Publications, will be of immense benefit and interest to you and the medical professions, particularly from a safety and marketing perspective. These will also reinforce the product ROWATINEX as an effective and safe medicine in the treatment of calculi fragments generated by ESWL.
ROWATINEX is the first choice in the treatment of Urolithiasis – therefore it is essential to receive your comments, marketing strategy, proposals for Meetings / Symposiums with key Urologists with view to undertaking an aggressive promotional campaign.